Publications
Information about journal articles, updated at 18-05-2025, from platform CIÊNCIAVITAE.
Genetic Alterations and Deregulation of Hippo Pathway as a Pathogenetic Mechanism in Bone and Soft Tissue Sarcoma
Ana Amaral; Carmen Salguero Aranda; Joaquín Olmedo-Pelayo; Enrique de Alava; Ana Teresa Amaral; Juan Diaz-Martin, Cancers. 6211 - 6211. 24. 14. 2022. http://dx.doi.org/10.3390/cancers14246211 . 10.3390/cancers14246211 . Cancers
Endoglin and MMP14 Contribute to Ewing Sarcoma Spreading by Modulation of Cell–Matrix Interactions
Puerto-Camacho, Pilar; Díaz-Martín, Juan; Olmedo-Pelayo, Joaquín; Bolado-Carrancio, Alfonso; Salguero-Aranda, Carmen; Jordán-Pérez, Carmen; Esteban-Medina, Marina; et al, International Journal of Molecular Sciences. 15. 23. 2022. http://dx.doi.org/10.3390/ijms23158657 . 10.3390/ijms23158657 . published International Journal of Molecular Sciences
Selective modulation by PARP-1 of HIF-1a-recruitment to chromatin during hypoxia is required for tumor adaptation to hypoxic conditions
Martí, Juan Manuel; Garcia-Diaz, Angel; Delgado-Bellido, Daniel; O'Valle, Francisco; González-Flores, Ariannys; Carlevaris, Onintza; Rodríguez-Vargas, José Manuel; et al, Redox Biology. 41. 2021. http://dx.doi.org/10.1016/j.redox.2021.101885 . 10.1016/j.redox.2021.101885 . Redox Biology
Endoglin in the Spotlight to Treat Cancer
González Muñoz, Teresa; Amaral, Ana Teresa; Puerto-Camacho, Pilar; Peinado, Héctor; de Álava, Enrique, International Journal of Molecular Sciences. 6. 22. 2021. http://dx.doi.org/10.3390/ijms22063186 . 10.3390/ijms22063186 . International Journal of Molecular Sciences
Hippo pathway effectors YAP1/TAZ induce an EWS–FLI1 -opposing gene signature and associate with disease progression in Ewing sarcoma
The Journal of Pathology. 374 - 386. 4. 250. 2020. http://dx.doi.org/10.1002/path.5379 . 10.1002/path.5379 . The Journal of Pathology
Breakthrough Technologies Reshape the Ewing Sarcoma Molecular Landscape
Cells. 804 - 804. 4. 9. 2020. http://dx.doi.org/10.3390/cells9040804 . 10.3390/cells9040804 . Cells
Preclinical Efficacy of Endoglin-Targeting Antibody–Drug Conjugates for the Treatment of Ewing Sarcoma
Clinical Cancer Research. 2228 - 2240. 7. 25. 2019. http://dx.doi.org/10.1158/1078-0432.ccr-18-0936 . 10.1158/1078-0432.ccr-18-0936 . Clinical Cancer Research
DNA methylation heterogeneity defines a disease spectrum in Ewing sarcoma
Nature Medicine. 386 - 395. 3. 23. 2017. http://dx.doi.org/10.1038/nm.4273 . 10.1038/nm.4273 . Nature Medicine
Ex vivo identification and characterization of a population of CD13high CD105+ CD45- mesenchymal stem cells in human bone marrow
Stem Cell Research & Therapy. 1. 6. 2015. http://dx.doi.org/10.1186/s13287-015-0152-8 . 10.1186/s13287-015-0152-8 . Stem Cell Research & Therapy
The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin
Oncotarget. 18875 - 18890. 22. 6. 2015. http://dx.doi.org/10.18632/oncotarget.4303 . 10.18632/oncotarget.4303 . Oncotarget
Trabectedin Efficacy in Ewing Sarcoma Is Greatly Increased by Combination with Anti-IGF Signaling Agents
Clinical Cancer Research. 1373 - 1382. 6. 21. 2015. http://dx.doi.org/10.1158/1078-0432.ccr-14-1688 . 10.1158/1078-0432.ccr-14-1688 . Clinical Cancer Research
Bone microenvironment signals in osteosarcoma development
Cellular and Molecular Life Sciences. 3097 - 3113. 16. 72. 2015. http://dx.doi.org/10.1007/s00018-015-1918-y . 10.1007/s00018-015-1918-y . Cellular and Molecular Life Sciences
Characterization of Human Mesenchymal Stem Cells from Ewing Sarcoma Patients. Pathogenetic Implications
PLoS ONE. e85814 - e85814. 2. 9. 2014. http://dx.doi.org/10.1371/journal.pone.0085814 . 10.1371/journal.pone.0085814 . PLoS ONE
Innovative Therapies in Ewing Sarcoma
Advances in Anatomic Pathology. 44 - 62. 1. 21. 2014. http://dx.doi.org/10.1097/pap.0000000000000003 . 10.1097/pap.0000000000000003 . Advances in Anatomic Pathology
IGF1R Signaling in Ewing Sarcoma Is Shaped by Clathrin-/Caveolin-Dependent Endocytosis
PLoS ONE. e19846 - e19846. 5. 6. 2011. http://dx.doi.org/10.1371/journal.pone.0019846 . 10.1371/journal.pone.0019846 . PLoS ONE
The Clinical Relevance of Molecular Genetics in Soft Tissue Sarcomas
Advances in Anatomic Pathology. 162 - 181. 3. 17. 2010. http://dx.doi.org/10.1097/pap.0b013e3181d98cbf . 10.1097/pap.0b013e3181d98cbf . Advances in Anatomic Pathology
Stable interference of EWS–FLI1 in an Ewing sarcoma cell line impairs IGF-1/IGF-1R signalling and reveals TOPK as a new target
British Journal of Cancer. 80 - 90. 1. 101. 2009. http://dx.doi.org/10.1038/sj.bjc.6605104 . 10.1038/sj.bjc.6605104 . British Journal of Cancer
5 17 out of 17 Publications
All projects
Information of exclusive responsibility of the researcher 18-05-2025 , from platform CIÊNCIAVITAE.
2024/01/09 - 2026/08/31
ERA Fellowships (HORIZON-WIDERA-2022-TALENTS-04)
101110890
Post-doc
2023/05/01 - 2024/08/31
CInTech: Technological Hub for Innovation, Translation and Industrialization of Complex Injectable Drugs
C644865576-00000005
Post-doc Fellow
Universidade de Coimbra; Bluepharma
2022/01/01 - 2023
Tailored adoptive cellular immunotherapy for Ewing Sarcoma
CI21-00189
Post-doc
Instituto de Biomedicina de Sevilla; Fundación Josep Carreras contra la Leucemia
Funders: Obra Social La Caixa
2021 - 2023
Integrative molecular-testing platform for precision diagnostics and personalized care of sarcoma patients
4becatrienalGEISFMJC
Post-doc
Instituto de Biomedicina de Sevilla; Hospital Universitario Virgen del Rocío
Funders: Fundacion Maripaz Jimenez Casado
2021 - 2022
Intratumoral heterogeneity in t-sarcomas: A silver lining for precision therapeutics
PI20-0003
Post-doc
Instituto de Biomedicina de Sevilla
Funders: Instituto de Salud Carlos III
2020 - 2022
Evaluación de STAT6 como biomarcador de diagnóstico de precisión y diana terapéutica en Tumor Fibroso Solitario
PI-0061-2020
Post-doc
Instituto de Biomedicina de Sevilla; Hospital Universitario Virgen del Rocío
Funders: Junta de Andalucía
2020 - 2023
New insights into the Desmoplastic small round cell tumour: comprehensive molecular characterization to identify therapeutic targets and new biomarkers
400300200313
Principal investigator
Instituto de Biomedicina de Sevilla
Funders: Grupo Espanol Investigacion Sarcomas
2020 - 2023
Study of the prognostic and functional role of mesenchymal stem cell markers Endoglin and ALCAM in the disease progression of Clear cell sarcomas (CCS) and Desmoplastic small Round cell tumors (DSRCT)
P18-RT-735
Principal investigator
Instituto de Biomedicina de Sevilla
Funders: Junta de Andalucía
2019 - 2022/12
CIBERONC-Centro de Investigacio Biomedica en RED: Low prevalence tumours program
G85296226
Post-doc
Centro de Investigación Biomédica en Red de Cáncer
2019 - 2023
Translational assessment of predictive factors of response of Ewing sarcoma to genotoxic therapy
S1900239
Principal investigator
Instituto de Biomedicina de Sevilla; Hospital Universitario Virgen del Rocío; University College London; University of Michigan
Funders: Sarcoma Foundation of America
2018 - 2019
PROYECTO 3D-ID CULTIVOS 3D PERSONALIZADOS PARA SELECCIÓN DE TRATAMIENTO PARA PACIENTES DE CÁNCER EN MEDICINA DE PRECISIÓN
RTC-2017-6573-1
Post-doc
Instituto de Biomedicina de Sevilla; STEMTEK THERAPEUTICS SL; FUNDACIÓN ONKOLOGIKOA FUNDAZIOA; Institut d'Investigació Biomèdica de Bellvitge
2018 - 2020
Nuevas dianas terapéuticas en el sarcoma de Ewing a través del estudio del proceso metastásico
PI1700464
Post-doc
Instituto de Biomedicina de Sevilla
Funders: Instituto de Salud Carlos III
2018 - 2021
Evaluation of the clinical potential of the vesicular crosstalk in response to drugs in the context of Ewing sarcoma. PI-0040-2017
PI-0040-2017
Principal investigator
Instituto de Biomedicina de Sevilla
Funders: Junta de Andalucía
2017 - 2018
PROspective VAlidation of Biomarkers in Ewing Sarcoma for personalized translational medicine
PI2/03102
Post-doc
Hospital Universitario Virgen del Rocío; IRCCS Istituto Ortopedico Rizzoli; St James's University Hospital; Institut Curie; Klinikum rechts der Isar der Technischen Universität München
Funders: European Commission
2014 - 2016
ENDOWING RELEVANCIA DE LA ENDOGLINA EN LA PATOLOGÍA DEL SARCOMA DE EWING: DESARROLLO DE TRATAMIENTOS PERSONALIZADOS INNOVADORES
RTC-2014-2102-1
Post-doc
Instituto de Biomedicina de Sevilla; Oncomatryx
2014 - 2017
Nuevas dianas terapéuticas en el sarcoma de Ewing: estudio del micromedioambiente
PI14/01466
Post-doc
Instituto de Biomedicina de Sevilla
Funders: Instituto de Salud Carlos III
5 16 out of 16 projects
We use cookies to improve your visit to our website.
